Abstract Search

ob0004p3 | Presented Posters | OU2024

Proposed prioritisation framework for the introduction of new medical therapies for weight management in the NHS

Boyle Luke D , Albor Christo , Anyiam Oluwaseun , Sen Gupta Piya , Coelho Claudia , Crane James , K Dimitriadis Georgios , Andrews Robert , Hughes David , Idris Iskandar , Tan Tricia , M McGowan Barbara , McCullough Kath

Until recently, only two medications were licenced and approved by the National Institute of Health and Care Excellence (NICE) for weight loss, orlistat and liraglutide. Semaglutide 2.4mg was launched in September 2023. Both liraglutide and semaglutide belong to a class of drugs called GLP-1 analogues, also used in the treatment of Type 2 diabetes. Successful weight loss outcomes for GLP-1 analogues has led to increased global demand and shortages. In June 2023, a National Pat...

0 shares

Obesity Abstracts

Proposed prioritisation framework for the introduction of new medical therapies for weight management in the NHS

BiosciAbstracts